Global Argininemia Treatment Market

Argininemia Treatment Comprehensive Study by Type (Oral, Injection), End Users (Hospitals, Clinics, Therapeutic Centres), Category (Congenital and Genetic Diseases, Metabolic disorders, RDCRN), Treatment (Dietary Proteins, Nitrogen-Scavenging Medications, Intravenous (IV) Fluids, Amino Acids) Players and Region - Global Market Outlook to 2028

Argininemia Treatment Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Argininemia Treatment
Argininemia (ARG) is a disorder in which dangerous levels of arginine and ammonia accumulate in the body. It is classified as an amino acid disorder because persons with ARG are unable to break down arginine, an amino acid, a tiny molecule that builds up proteins. Treatment for arginine mix is nutritional, including protein restriction and amino acid supplementation. Individuals with arginine mix can typically live healthily lives if the illness is diagnosed early and effective therapy is undertaken. Argininemia is a rare disorder and few patients have been treated from an early age, prior to onset of disabling symptoms. Dietary restriction of protein is the basic treatment, with supporting therapy to prevent and control the hyperammonemia. Because the diagnosis and therapy of argininemia is complex, the pediatrician is advised to manage the patient in close collaboration with a consulting pediatric metabolic disease specialist. It is recommended that parents travel with a letter of treatment guidelines from the patient’s physician.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


The demand for Argininemia Treatment is increasing due to its rising progressive and devastating nature with each passing day. The Companies in this industry are facing fierce competition. Many global and regional service providers compete directly with industry leaders in this field. It has been identified that market-leading players are investing heavily in technological development, resource utilization to boost the market position. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Argininemia Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

BabyFirst (United States), Invitae (United States), TriHealth (United States), Aeglea Bio Therapeutics Inc (United States), Sigma-Aldrich (United States), R & D Systems (United States), ACROBiosystems (United States) and Breda Genetics srl (Italy) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Orphanet (France), Mendelian Health (United Kingdom), Asbbs (United States), Novus Biologicals (United States) and VarSome (China).

Segmentation Overview
AMA Research has segmented the market of Global Argininemia Treatment market by Type (Oral and Injection) and Region.



On the basis of geography, the market of Argininemia Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Users, the sub-segment i.e. Hospitals will boost the Argininemia Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Category, the sub-segment i.e. Congenital and Genetic Diseases will boost the Argininemia Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Treatment, the sub-segment i.e. Dietary Proteins will boost the Argininemia Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
The Emergence of Lipid Nanoparticle-Targeted mRNA Therapy

Market Growth Drivers:
Increasing Incidents of Urea Cycle Disorders and Rising Awareness of Argininemia

Challenges:
Lack of Awareness Regarding Argininemia Treatment and Argininemia Treatment is Very Expensive

Restraints:
Argininemia Treatment May Cause Some Side Effects Such as Poor Growth and Stiff Muscles

Opportunities:
Rise in Ammonia Deficiency in Babies and Emerging Technologies and Precision Medicine

Market Leaders and their expansionary development strategies
In May 2023, Horizon Therapeutics acquires Metanomics, gaining access to investigational gene therapy MT007 for argininemia. This acquisition brings MT007, a potentially curative gene therapy, closer to the market, offering a long-term treatment option for argininemia patients.
In March 2023, BioMarin Pharmaceuticals receives FDA approval for Palynziq (pegdefibrotide) oral granules for the treatment of argininemia. This groundbreaking approval provides a convenient and easier-to-administer option for patients, replacing the previously available injectable form of pegdefibrotide.


Key Target Audience
Venture and Capitalist, Raw Materials Suppliers, New Entrants/Investors, Healthcare and End-Use Industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Oral
  • Injection
By End Users
  • Hospitals
  • Clinics
  • Therapeutic Centres

By Category
  • Congenital and Genetic Diseases
  • Metabolic disorders
  • RDCRN

By Treatment
  • Dietary Proteins
  • Nitrogen-Scavenging Medications
  • Intravenous (IV) Fluids
  • Amino Acids

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidents of Urea Cycle Disorders
      • 3.2.2. Rising Awareness of Argininemia
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness Regarding Argininemia Treatment
      • 3.3.2. Argininemia Treatment is Very Expensive
    • 3.4. Market Trends
      • 3.4.1. The Emergence of Lipid Nanoparticle-Targeted mRNA Therapy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Argininemia Treatment, by Type, End Users, Category, Treatment and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Argininemia Treatment (Value)
      • 5.2.1. Global Argininemia Treatment by: Type (Value)
        • 5.2.1.1. Oral
        • 5.2.1.2. Injection
      • 5.2.2. Global Argininemia Treatment by: End Users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Therapeutic Centres
      • 5.2.3. Global Argininemia Treatment by: Category (Value)
        • 5.2.3.1. Congenital and Genetic Diseases
        • 5.2.3.2. Metabolic disorders
        • 5.2.3.3. RDCRN
      • 5.2.4. Global Argininemia Treatment by: Treatment (Value)
        • 5.2.4.1. Dietary Proteins
        • 5.2.4.2. Nitrogen-Scavenging Medications
        • 5.2.4.3. Intravenous (IV) Fluids
        • 5.2.4.4. Amino Acids
      • 5.2.5. Global Argininemia Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Argininemia Treatment (Price)
      • 5.3.1. Global Argininemia Treatment by: Type (Price)
  • 6. Argininemia Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. BabyFirst (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Invitae (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. TriHealth (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Aeglea Bio Therapeutics Inc (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sigma-Aldrich (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. R & D Systems (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. ACROBiosystems (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Breda Genetics srl (Italy)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Argininemia Treatment Sale, by Type, End Users, Category, Treatment and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Argininemia Treatment (Value)
      • 7.2.1. Global Argininemia Treatment by: Type (Value)
        • 7.2.1.1. Oral
        • 7.2.1.2. Injection
      • 7.2.2. Global Argininemia Treatment by: End Users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Therapeutic Centres
      • 7.2.3. Global Argininemia Treatment by: Category (Value)
        • 7.2.3.1. Congenital and Genetic Diseases
        • 7.2.3.2. Metabolic disorders
        • 7.2.3.3. RDCRN
      • 7.2.4. Global Argininemia Treatment by: Treatment (Value)
        • 7.2.4.1. Dietary Proteins
        • 7.2.4.2. Nitrogen-Scavenging Medications
        • 7.2.4.3. Intravenous (IV) Fluids
        • 7.2.4.4. Amino Acids
      • 7.2.5. Global Argininemia Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Argininemia Treatment (Price)
      • 7.3.1. Global Argininemia Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Argininemia Treatment: by Type(USD Million)
  • Table 2. Argininemia Treatment Oral , by Region USD Million (2017-2022)
  • Table 3. Argininemia Treatment Injection , by Region USD Million (2017-2022)
  • Table 4. Argininemia Treatment: by End Users(USD Million)
  • Table 5. Argininemia Treatment Hospitals , by Region USD Million (2017-2022)
  • Table 6. Argininemia Treatment Clinics , by Region USD Million (2017-2022)
  • Table 7. Argininemia Treatment Therapeutic Centres , by Region USD Million (2017-2022)
  • Table 8. Argininemia Treatment: by Category(USD Million)
  • Table 9. Argininemia Treatment Congenital and Genetic Diseases , by Region USD Million (2017-2022)
  • Table 10. Argininemia Treatment Metabolic disorders , by Region USD Million (2017-2022)
  • Table 11. Argininemia Treatment RDCRN , by Region USD Million (2017-2022)
  • Table 12. Argininemia Treatment: by Treatment(USD Million)
  • Table 13. Argininemia Treatment Dietary Proteins , by Region USD Million (2017-2022)
  • Table 14. Argininemia Treatment Nitrogen-Scavenging Medications , by Region USD Million (2017-2022)
  • Table 15. Argininemia Treatment Intravenous (IV) Fluids , by Region USD Million (2017-2022)
  • Table 16. Argininemia Treatment Amino Acids , by Region USD Million (2017-2022)
  • Table 17. South America Argininemia Treatment, by Country USD Million (2017-2022)
  • Table 18. South America Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 19. South America Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 20. South America Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 21. South America Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 22. Brazil Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 23. Brazil Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 24. Brazil Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 25. Brazil Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 26. Argentina Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 27. Argentina Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 28. Argentina Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 29. Argentina Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 30. Rest of South America Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 31. Rest of South America Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 32. Rest of South America Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 33. Rest of South America Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 34. Asia Pacific Argininemia Treatment, by Country USD Million (2017-2022)
  • Table 35. Asia Pacific Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 36. Asia Pacific Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 37. Asia Pacific Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 38. Asia Pacific Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 39. China Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 40. China Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 41. China Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 42. China Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 43. Japan Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 44. Japan Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 45. Japan Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 46. Japan Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 47. India Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 48. India Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 49. India Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 50. India Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 51. South Korea Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 52. South Korea Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 53. South Korea Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 54. South Korea Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 55. Australia Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 56. Australia Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 57. Australia Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 58. Australia Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 59. Rest of Asia-Pacific Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 60. Rest of Asia-Pacific Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 61. Rest of Asia-Pacific Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 62. Rest of Asia-Pacific Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 63. Europe Argininemia Treatment, by Country USD Million (2017-2022)
  • Table 64. Europe Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 65. Europe Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 66. Europe Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 67. Europe Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 68. Germany Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 69. Germany Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 70. Germany Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 71. Germany Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 72. France Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 73. France Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 74. France Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 75. France Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 76. Italy Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 77. Italy Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 78. Italy Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 79. Italy Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 80. United Kingdom Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 81. United Kingdom Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 82. United Kingdom Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 83. United Kingdom Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 84. Netherlands Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 85. Netherlands Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 86. Netherlands Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 87. Netherlands Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 88. Rest of Europe Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 89. Rest of Europe Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 90. Rest of Europe Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 91. Rest of Europe Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 92. MEA Argininemia Treatment, by Country USD Million (2017-2022)
  • Table 93. MEA Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 94. MEA Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 95. MEA Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 96. MEA Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 97. Middle East Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 98. Middle East Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 99. Middle East Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 100. Middle East Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 101. Africa Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 102. Africa Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 103. Africa Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 104. Africa Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 105. North America Argininemia Treatment, by Country USD Million (2017-2022)
  • Table 106. North America Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 107. North America Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 108. North America Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 109. North America Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 110. United States Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 111. United States Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 112. United States Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 113. United States Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 114. Canada Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 115. Canada Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 116. Canada Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 117. Canada Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 118. Mexico Argininemia Treatment, by Type USD Million (2017-2022)
  • Table 119. Mexico Argininemia Treatment, by End Users USD Million (2017-2022)
  • Table 120. Mexico Argininemia Treatment, by Category USD Million (2017-2022)
  • Table 121. Mexico Argininemia Treatment, by Treatment USD Million (2017-2022)
  • Table 122. Argininemia Treatment: by Type(USD/Units)
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Argininemia Treatment: by Type(USD Million)
  • Table 132. Argininemia Treatment Oral , by Region USD Million (2023-2028)
  • Table 133. Argininemia Treatment Injection , by Region USD Million (2023-2028)
  • Table 134. Argininemia Treatment: by End Users(USD Million)
  • Table 135. Argininemia Treatment Hospitals , by Region USD Million (2023-2028)
  • Table 136. Argininemia Treatment Clinics , by Region USD Million (2023-2028)
  • Table 137. Argininemia Treatment Therapeutic Centres , by Region USD Million (2023-2028)
  • Table 138. Argininemia Treatment: by Category(USD Million)
  • Table 139. Argininemia Treatment Congenital and Genetic Diseases , by Region USD Million (2023-2028)
  • Table 140. Argininemia Treatment Metabolic disorders , by Region USD Million (2023-2028)
  • Table 141. Argininemia Treatment RDCRN , by Region USD Million (2023-2028)
  • Table 142. Argininemia Treatment: by Treatment(USD Million)
  • Table 143. Argininemia Treatment Dietary Proteins , by Region USD Million (2023-2028)
  • Table 144. Argininemia Treatment Nitrogen-Scavenging Medications , by Region USD Million (2023-2028)
  • Table 145. Argininemia Treatment Intravenous (IV) Fluids , by Region USD Million (2023-2028)
  • Table 146. Argininemia Treatment Amino Acids , by Region USD Million (2023-2028)
  • Table 147. South America Argininemia Treatment, by Country USD Million (2023-2028)
  • Table 148. South America Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 149. South America Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 150. South America Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 151. South America Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 152. Brazil Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 153. Brazil Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 154. Brazil Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 155. Brazil Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 156. Argentina Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 157. Argentina Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 158. Argentina Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 159. Argentina Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 160. Rest of South America Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 161. Rest of South America Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 162. Rest of South America Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 163. Rest of South America Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 164. Asia Pacific Argininemia Treatment, by Country USD Million (2023-2028)
  • Table 165. Asia Pacific Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 166. Asia Pacific Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 167. Asia Pacific Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 168. Asia Pacific Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 169. China Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 170. China Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 171. China Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 172. China Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 173. Japan Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 174. Japan Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 175. Japan Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 176. Japan Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 177. India Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 178. India Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 179. India Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 180. India Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 181. South Korea Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 182. South Korea Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 183. South Korea Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 184. South Korea Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 185. Australia Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 186. Australia Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 187. Australia Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 188. Australia Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 189. Rest of Asia-Pacific Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 190. Rest of Asia-Pacific Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 191. Rest of Asia-Pacific Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 192. Rest of Asia-Pacific Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 193. Europe Argininemia Treatment, by Country USD Million (2023-2028)
  • Table 194. Europe Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 195. Europe Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 196. Europe Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 197. Europe Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 198. Germany Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 199. Germany Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 200. Germany Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 201. Germany Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 202. France Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 203. France Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 204. France Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 205. France Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 206. Italy Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 207. Italy Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 208. Italy Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 209. Italy Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 210. United Kingdom Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 211. United Kingdom Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 212. United Kingdom Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 213. United Kingdom Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 214. Netherlands Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 215. Netherlands Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 216. Netherlands Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 217. Netherlands Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 218. Rest of Europe Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 219. Rest of Europe Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 220. Rest of Europe Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 221. Rest of Europe Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 222. MEA Argininemia Treatment, by Country USD Million (2023-2028)
  • Table 223. MEA Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 224. MEA Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 225. MEA Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 226. MEA Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 227. Middle East Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 228. Middle East Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 229. Middle East Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 230. Middle East Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 231. Africa Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 232. Africa Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 233. Africa Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 234. Africa Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 235. North America Argininemia Treatment, by Country USD Million (2023-2028)
  • Table 236. North America Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 237. North America Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 238. North America Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 239. North America Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 240. United States Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 241. United States Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 242. United States Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 243. United States Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 244. Canada Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 245. Canada Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 246. Canada Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 247. Canada Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 248. Mexico Argininemia Treatment, by Type USD Million (2023-2028)
  • Table 249. Mexico Argininemia Treatment, by End Users USD Million (2023-2028)
  • Table 250. Mexico Argininemia Treatment, by Category USD Million (2023-2028)
  • Table 251. Mexico Argininemia Treatment, by Treatment USD Million (2023-2028)
  • Table 252. Argininemia Treatment: by Type(USD/Units)
  • Table 253. Research Programs/Design for This Report
  • Table 254. Key Data Information from Secondary Sources
  • Table 255. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Argininemia Treatment: by Type USD Million (2017-2022)
  • Figure 5. Global Argininemia Treatment: by End Users USD Million (2017-2022)
  • Figure 6. Global Argininemia Treatment: by Category USD Million (2017-2022)
  • Figure 7. Global Argininemia Treatment: by Treatment USD Million (2017-2022)
  • Figure 8. South America Argininemia Treatment Share (%), by Country
  • Figure 9. Asia Pacific Argininemia Treatment Share (%), by Country
  • Figure 10. Europe Argininemia Treatment Share (%), by Country
  • Figure 11. MEA Argininemia Treatment Share (%), by Country
  • Figure 12. North America Argininemia Treatment Share (%), by Country
  • Figure 13. Global Argininemia Treatment: by Type USD/Units (2017-2022)
  • Figure 14. Global Argininemia Treatment share by Players 2022 (%)
  • Figure 15. Global Argininemia Treatment share by Players (Top 3) 2022(%)
  • Figure 16. Global Argininemia Treatment share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. BabyFirst (United States) Revenue, Net Income and Gross profit
  • Figure 19. BabyFirst (United States) Revenue: by Geography 2022
  • Figure 20. Invitae (United States) Revenue, Net Income and Gross profit
  • Figure 21. Invitae (United States) Revenue: by Geography 2022
  • Figure 22. TriHealth (United States) Revenue, Net Income and Gross profit
  • Figure 23. TriHealth (United States) Revenue: by Geography 2022
  • Figure 24. Aeglea Bio Therapeutics Inc (United States) Revenue, Net Income and Gross profit
  • Figure 25. Aeglea Bio Therapeutics Inc (United States) Revenue: by Geography 2022
  • Figure 26. Sigma-Aldrich (United States) Revenue, Net Income and Gross profit
  • Figure 27. Sigma-Aldrich (United States) Revenue: by Geography 2022
  • Figure 28. R & D Systems (United States) Revenue, Net Income and Gross profit
  • Figure 29. R & D Systems (United States) Revenue: by Geography 2022
  • Figure 30. ACROBiosystems (United States) Revenue, Net Income and Gross profit
  • Figure 31. ACROBiosystems (United States) Revenue: by Geography 2022
  • Figure 32. Breda Genetics srl (Italy) Revenue, Net Income and Gross profit
  • Figure 33. Breda Genetics srl (Italy) Revenue: by Geography 2022
  • Figure 34. Global Argininemia Treatment: by Type USD Million (2023-2028)
  • Figure 35. Global Argininemia Treatment: by End Users USD Million (2023-2028)
  • Figure 36. Global Argininemia Treatment: by Category USD Million (2023-2028)
  • Figure 37. Global Argininemia Treatment: by Treatment USD Million (2023-2028)
  • Figure 38. South America Argininemia Treatment Share (%), by Country
  • Figure 39. Asia Pacific Argininemia Treatment Share (%), by Country
  • Figure 40. Europe Argininemia Treatment Share (%), by Country
  • Figure 41. MEA Argininemia Treatment Share (%), by Country
  • Figure 42. North America Argininemia Treatment Share (%), by Country
  • Figure 43. Global Argininemia Treatment: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • BabyFirst (United States)
  • Invitae (United States)
  • TriHealth (United States)
  • Aeglea Bio Therapeutics Inc (United States)
  • Sigma-Aldrich (United States)
  • R & D Systems (United States)
  • ACROBiosystems (United States)
  • Breda Genetics srl (Italy)
Additional players considered in the study are as follows:
Orphanet (France) , Mendelian Health (United Kingdom) , Asbbs (United States) , Novus Biologicals (United States) , VarSome (China) ,
Select User Access Type

Key Highlights of Report


Jan 2024 244 Pages 96 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Argininemia Treatment Market Quantitative research analysis
Global Argininemia Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as BabyFirst (United States), Invitae (United States), TriHealth (United States), Aeglea Bio Therapeutics Inc (United States), Sigma-Aldrich (United States), R & D Systems (United States), ACROBiosystems (United States) and Breda Genetics srl (Italy) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"The Emergence of Lipid Nanoparticle-Targeted mRNA Therapy" is seen as one of major influencing trends for Argininemia Treatment Market during projected period 2022-2028.
The Argininemia Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Argininemia Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Dynamic SPECT Comprehensive Study by Application (Myocardial perfusion imaging, Functional brain imaging, Applications in nuclear technology, Others), Imaging Technique (Hybrid SPECT, Standalone SPEC...
$ 3750
Picato Gel Comprehensive Study by Type (Type I, Type II), Application (Actinic Keratosis, Keratosis), Distribution Channel (Direct Sale, Distributor) Players and Region - Global Market Outlook to 203...
$ 3500
Soft Tissue Repair Comprehensive Study by Type (Fixation Products (Suture, Suture Anchors, Interference Screw), Tissue Patch/Match (Biological {Allograft, Xenograft},Synthetic), Laparoscopic Instrume...
$ 3750
Onychomycosis Treatment Comprehensive Study by Application (Hospitals, Dermatology Clinics, Retail Pharmacies, Online Pharmacies), Treatment (Systemic Antifungal Agents, Lasers, Photodynamic Therapy,...
$ 3750
Veterinary Clostridium Vaccine Comprehensive Study by Type (Bovine, Ovine, Caprine, Swine, Poultry), Application (Veterinary Clinic, Veterinary Hospital, Veterinary Research Institute, Retail Pharmac...
$ 3650
Lumpectomy Comprehensive Study by Type (Surgical Tools, Lumpectomy Systems), End User (Hospitals, Clinics, Ambulatory Surgical Centers) Players and Region - Global Market Outlook to 2030
$ 3500